70
Participants
Start Date
December 7, 2017
Primary Completion Date
December 31, 2022
Study Completion Date
July 17, 2026
Bevacizumab
Given IV
Cediranib
Given PO
Cediranib Maleate
Given PO
Olaparib
Given PO
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Duke University Medical Center, Durham
Moffitt Cancer Center, Tampa
University of Kentucky/Markey Cancer Center, Lexington
Ohio State University Comprehensive Cancer Center, Columbus
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
Siteman Cancer Center at Christian Hospital, St Louis
Siteman Cancer Center at West County Hospital, Creve Coeur
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
UCHealth University of Colorado Hospital, Aurora
UC San Diego Moores Cancer Center, La Jolla
Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center - Guilford, Guilford
Smilow Cancer Hospital Care Center at Saint Francis, Hartford
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
Smilow Cancer Hospital-Orange Care Center, Orange
Smilow Cancer Hospital-Torrington Care Center, Torrington
Smilow Cancer Hospital Care Center-Trumbull, Trumbull
Smilow Cancer Hospital-Waterbury Care Center, Waterbury
Smilow Cancer Hospital Care Center - Waterford, Waterford
Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH